Investors of Alto Neuroscience, Inc. are urged to get in touch with the Portnoy Law Firm to recoup their losses. The deadline to submit the Lead Plaintiff Motion is September 19, 2025.

In a significant development, The Portnoy Law Firm has announced the filing of a class action lawsuit against Alto Neuroscience, a clinical-stage biopharmaceutical company. The lawsuit alleges that the company made false or misleading statements and failed to disclose important information regarding its product, ALTO-100, used for treating Major Depressive Disorder (MDD).

The announcement of the topline results from the Phase 2b trial of ALTO-100 for MDD, on October 22, 2024, revealed that the drug did not meet its primary endpoint. Consequently, the company's stock fell nearly 70%.

The class action represents investors who bought securities between February 2, 2024, and October 22, 2024. The lawsuit specifically alleges that ALTO-100 was less effective in treating MDD than represented. As of the filing of the Alto Neuroscience class action, the price of Alto Neuroscience common stock continues to trade below the IPO price of $16.00 per share.

Investors who purchased Alto Neuroscience securities during the specified period are encouraged to contact attorney Lesley F. Portnoy for a complimentary case evaluation. Lesley F. Portnoy, Esq., the founding partner of The Portnoy Law Firm, has recovered over $5.5 billion for aggrieved investors.

Lesley F. Portnoy can be contacted at [email protected] or by phone at 310-692-8883. The Portnoy Law Firm's website, www.portnoylaw.com, provides more information and allows for transaction submission.

It is important to note that prior results obtained by The Portnoy Law Firm do not guarantee similar outcomes. The Portnoy Law Firm represents investors in pursuing claims against companies due to corporate wrongdoing. The Portnoy Law Firm's advertising is subject to attorney advertising regulations. Lesley F. Portnoy is admitted to practice law in California and New York.

The deadline to file a lead plaintiff motion is September 19, 2025. Investors are urged to act promptly if they wish to obtain more information about the Alto Neuroscience class action lawsuit.

Investors should carefully consider their options and seek legal advice from a qualified securities attorney to ensure their best interests are protected.